课题基金 / 基金详情

PSA velocity in men starting 5-alpha-reductase inhibitors at the time of starting active surveillance is a predictor of pathological progression in low-risk prostate cancer

PSA velocity in men starting 5-alpha-reductase inhibitors at the time of starting active surveillance is a predictor of pathological progression in low-risk prostate cancer
在开始主动监测时开始使用 5-α 还原酶抑制剂的男性 PSA 速度是低风险前列腺癌病理进展的预测因子
批准号：
364535
负责人：
Timilshina NARHARI
金额：
$0.07万
依托单位：
University Health Network (Toronto)
依托单位国家：
加拿大
项目类别：
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-01-01 至 2018-01-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=364535&lang=en
关键词：
Active Surveillance Progression Prostate Cancer Psa Velocity

项目摘要

项目成果

Timilshina NARHARI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
INTRODUCTION: 5-alpha-reductase inhibitors (5ARI) are being increasingly used among low-risk active surveillance (AS) patients. The REDUCE trial suggested that 5ARIs may reduce the rate of pathological progression in men on AS. However, limited work has b
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improving the Canadian drug approval framework: Evaluation of effectiveness; safety and economic uncertainty associated with new cancer medicines using real world evidence
Initiation of Bhutan Cancer Registry: experiences, progress and future challenges from low-middle income country
  • 批准号：
    311309
  • 项目类别：
  • 资助金额：
    $0.11万
  • 财政年份：
    2014
  • 负责人：
    Timilshina NARHARI
  • 依托单位：
    University of Toronto
海外基金